Welcome to our dedicated page for Tela Bio news (Ticker: TELA), a resource for investors and traders seeking the latest updates and insights on Tela Bio stock.
TELA Bio, Inc. develops and commercializes soft-tissue reconstruction solutions for surgeons, with a focus on products designed to preserve and restore patient anatomy while limiting long-term exposure to permanent synthetic materials. Its OviTex portfolio includes configurations used in hernia repair and abdominal wall reconstruction, including ventral, inguinal and hiatal procedures.
Company news commonly covers quarterly and annual results, revenue guidance, commercial execution, product portfolio updates, credit and capital actions, board and leadership changes, and equity compensation grants made under Nasdaq inducement-grant rules.
TELA Bio announced encouraging results from the 12-month follow-up of its BRAVO study, involving 75 patients treated with OviTex Reinforced Tissue Matrix for ventral hernia repair. The data indicates a low hernia recurrence rate of 2.7%, with the final 24-month analysis showing rates below 5%. The study also reported low surgical site occurrences and significant improvements in patient quality of life. The results affirm TELA Bio's commitment to addressing the shortcomings of traditional hernia repair materials.
MALVERN, Pa., Nov. 08, 2021 - TELA Bio, Inc. (NASDAQ: TELA) announced its participation in key healthcare conferences, including the Canaccord Genuity MedTech Forum, Jefferies London Healthcare Conference, and Piper Sandler Healthcare Conference. Management will present on November 18 and 22, 2021. These events focus on TELA's innovative tissue reinforcement materials aimed at improving outcomes in soft tissue reconstruction. Live webcasts will be accessible for stakeholders.
TELA Bio has entered a distribution agreement with Next Science for the exclusive rights to market Next Science's proprietary antimicrobial surgical wash in the US, leveraging XBIO technology. This no-rinse solution provides over five hours of protection against bacterial biofilms, addressing a critical need in plastic reconstructive surgery. TELA also secured a right of first negotiation for the EU market upon CE approval. This partnership aims to enhance TELA's product offerings and improve infection control in surgical procedures.
TELA Bio, Inc. (NASDAQ: TELA) announced it will report its third quarter 2021 financial results on November 10, 2021, followed by a conference call at 4:30 p.m. ET. The company focuses on developing innovative tissue reinforcement materials for soft tissue reconstruction. Its products aim to improve clinical outcomes while minimizing the use of permanent synthetic materials. Investors can access the conference call by dialing specific numbers or through a webcast available on TELA's investor website.
TELA Bio, Inc. has appointed Roberto Cuca as the new Chief Operating Officer (COO) and Chief Financial Officer (CFO). With over 25 years of experience in the healthcare sector, including leadership roles at OraSure Technologies and Trevana, Cuca's expertise is expected to bolster TELA's operations and financial management. On his appointment date, he was granted an option to purchase 144,000 shares of TELA's common stock, indicating the company's confidence in his capabilities. The move aims to drive growth and enhance TELA’s strategic execution in tissue reinforcement technologies.
TELA Bio recently shared promising clinical results at the 2021 Society of American Gastrointestinal and Endoscopic Surgeons meeting, highlighting advancements in hernia repair solutions.
Key findings include a 2.7% recurrence rate and 1.8% surgical site occurrence rate using the OviTex in robotic-assisted procedures, demonstrating its efficacy as a natural repair alternative.
Further studies indicate a 1.3% recurrence rate across 619 implants with a unique surgical technique, underscoring the potential of OviTex in complex repairs.
TELA Bio (NASDAQ: TELA) announces three poster presentations highlighting the effectiveness of its OviTex Reinforced Tissue Matrix for hernia repairs at the SAGES conference from August 31 to September 3, 2021. The presentations will feature collaborative research from over 100 surgeons, showcasing innovative approaches such as the Reinforced Biologic Augmented Repair (ReBAR) technique. The company aims to provide advanced, biologically effective solutions that enhance surgical outcomes while minimizing the use of permanent synthetic materials.
On August 11, 2021, TELA Bio, Inc. (Nasdaq: TELA) announced its second quarter 2021 financial results, reporting a revenue of $7.6 million, reflecting a 116% year-over-year increase and a 29% rise from the previous quarter. The growth was attributed to increased demand for OviTex® products, particularly in robotic-assisted procedures. Gross profit improved to 67% of revenue. However, TELA incurred a net loss of $8.3 million, up from $6.1 million in Q2 2020. The company raised its revenue guidance for 2021 to between $28 million and $30 million, indicating a growth forecast of 54% to 65%.
MALVERN, Pa., Aug. 03, 2021 – TELA Bio, Inc. (NASDAQ: TELA) has announced its participation in Canaccord Genuity’s 41st Annual Growth Conference. Management will present on August 12, 2021, at 2:00 PM EDT. The company specializes in innovative tissue reinforcement materials aimed at enhancing soft tissue reconstruction outcomes. TELA’s OviTex® and OviTex PRS products are designed to improve hernia repair and abdominal wall reconstruction processes while minimizing reliance on synthetic materials.
TELA Bio, Inc. (NASDAQ: TELA), a medical technology company, announced it will report its second quarter 2021 financial results on August 11, 2021, at 4:30 p.m. ET. This report will cover financial highlights and provide a corporate update. TELA Bio specializes in innovative tissue reinforcement solutions for soft tissue reconstruction, aiming to improve patient outcomes while reducing the use of permanent synthetic materials. Their OviTex® products are designed for hernia repair and abdominal wall reconstruction.